Brief: GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650

GT Biopharma

30/08/2022 23:12

Aug 30 (Reuters) - GT Biopharma Inc  GTBP.O :
    * GT BIOPHARMA AFFIRMS MANUFACTURING TIMELINE FOR LEAD
INVESTIGATIONAL ASSET GTB-3650
    * GT BIOPHARMA INC - GTB-3650'S IND APPLICATION WITH FDA
EXPECTED
BY END OF Q1 OF 2023
    * GT BIOPHARMA INC - ENTERING INTO A SETTLEMENT AND
INVESTMENT
AGREEMENT WITH ITS CONTRACT MANUFACTURING PARTNER CYTOVANCE
BIOLOGICS
    * GT BIOPHARMA INC -  EXPECTS TO FILE ITS IND APPLICATION
WITH FDA
FOR ITS GTB-5550 PRODUCT NO LATER THAN JUNE 30, 2023

Source text for Eikon:  ID:nGNX25GX77 
Further company coverage:  GTBP.O 

 ((Reuters.Briefs@thomsonreuters.com;))